Company: BCS
Filing Date: 2025-02-21
Form Type: 424B2
Source: 0001193125-25-031790
Chunk: 30

Company: BARCLAYS PLC
Filing Date: 2025-02-21
Form: 424B2
Chunk 30
---
 York, United States. |

| Book-Entry Issuance, Denominations, Settlement and Clearance | We will issue the notes in fully registered form in denominations of $200,000 and integral multiples of $1,000 in excess thereof. Each series of notes will be represented by one or more global securities registered in the name of a nominee of        
 DTC. You will hold beneficial interests in the relevant notes through DTC and its direct and indirect participants, including Euroclear and Clearstream Luxembourg, and DTC and its direct and indirect participants will record your beneficial interest 
 on their books.                                                                                                                                                                                                                                           |

| We will not issue definitive certificated notes except in limited circumstances that we explain under “Description of Certain Provisions Relating to Debt Securities and Contingent Capital Securities—Special 
 Situations When a Global Security Will Be Terminated” in the accompanying prospectus.                                                                                                                          |

| Settlement of the notes will occur through DTC in same day funds. For information on DTC’s book-entry system, see “Clearance and Settlement—The Clearing Systems—DTC” in the accompanying 
 prospectus.                                                                                                                                                                               |

| Conflicts of Interest | Barclays Capital Inc., the Sole Structuring Adviser and Sole Bookrunner, is an affiliate of Barclays PLC and, as such, is deemed to have a “conflict of interest” in this offering within the meaning of Rule 5121 (or any successor rule 
 thereto) (“Rule 5121”) of the Financial Industry Regulatory Authority, Inc. (“FINRA”).                                                                                                                                                    |

| Consequently, this offering is being conducted in compliance with the provisions of Rule 5121. Barclays Capital Inc. is not permitted to sell any notes in this offering to an account over which it exercises 
 discretionary authority without the prior specific written approval of the account holder. For more information, see “Underwriting (Conflicts of Interest)—Conflicts of Interest.”                             |

| CUSIP | 2029 notes: 06738E CX1 |

2031 notes: 06738E CY9 2036 notes: 06738E CZ6

| ISIN | 2029 notes: US06738ECX13 |

2031 notes: US06738ECY95 2036 notes: US06738ECZ60

S-23

| Listing and Trading | We will apply to list the notes on the NYSE. Trading on the NYSE is expected to begin within 30 days of the initial delivery of the notes